Drug · Other

Calaspargase Pegol

CI-DRUG-00000760Explore in graph →CHEMBL2108728 Approved

Regulatory

Approvals (2)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory2 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as ASPARLAS (DIN 02542943) under ATC L01 ANTINEOPLASTIC AGENTS. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 16, 2024	health-canada-dpd
US FDA	Acute Lymphoblastic Leukemia	ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.	approved	Dec 20, 2018	openfda

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 21 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	18	9	7	22	2	CA, US	Dec 20, 2018	Jul 21, 2008
Leukemia	Approved	Phase 3	18	9	7	21	1	US	Dec 20, 2018	Jul 21, 2008
Non-Hodgkin Lymphoma	Phase3	Phase 3	7	4	3	8	0	—	—	Jun 19, 2017
Malignant Central Nervous System Neoplasm	Phase3	Phase 3	1	1	1	1	0

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (22)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–22 of 22 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06124157	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)	recruiting	Phase 2	222	National Cancer Institute (NCI)NIH	4	Sep 28, 2026	clinicaltrials
NCT06317662	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Molecule

Record

Kind: Other
Mechanism: Asparagine hydrolytic enzyme
UNII: T9FVH03HMZ
Aliases: ASPARLAS, Calaspargasa pegol, Calaspargase Pegol, Calaspargase pegol mknl, EZN-2285

Data updated 2 days agoSource updated unknown

Identifiers

Codes (3)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01	ANTINEOPLASTIC AGENTS
DIN (Health Canada)	02542943	ASPARLAS
DPD drug code	103146